Humoral Immunity Elicited by the XBB.1.5 Monovalent COVID-19 Vaccine.

Xammy Huu Nguyenla Timothy A Bates Mila Trank-GreeneMastura WahediFikadu G Tafesse Marcel E Curlin

Published in: medRxiv : the preprint server for health sciences (2024)

As novel SARS-CoV-2 variants continue to emerge, the updated XBB.1.5 monovalent vaccines remain to be evaluated in terms of immunogenicity against live clinical isolates. We report boosting of IgG(2.1X), IgA(1.5X), and total IgG/A/M(1.7X) antibodies targeting the spike receptor-binding domain and neutralizing titers against WA1(2.2X), XBB.1.5(7.4X), EG.5.1(10.5X), and JN.1(4.7X) variants.

Keyphrases

sars cov
copy number
respiratory syndrome coronavirus
immune response
coronavirus disease
cancer therapy
dengue virus
dna binding
transcription factor
drug delivery